NetraMark expects its insights potentially could protect millions of R&D dollars, increase drug development success rates, lower costs for drug sponsors & shorten the time to commercialization of new therapies. Developing & commercializing a new drug takes an avg 10-15 years & costs an avg $2.6B, while failure rates are nearly 90%. In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials & expects additional partnerships with other CROs & pharma companies. The addressable market is large & the adoption of AI to improve clinical trial efficiencies is rising. The company has a growing pipeline of leads & has already closed five deals with core midsized pharma companies.
